Spermosens presents plan to achieve positive cash flow following recent strategic investment
Spermosens AB (publ) (“Spermosens” or the “Company”) presents the plan to achieve positive cash flow following a recent investment by a consortium of investors from Germany, Scandinavia and the United States. The plan includes completion of the ongoing clinical study and advancing the JUNO-Checked technology and system to ensure commercial viability. Through this approach, Spermosens…
Spermosens AB (publ) ("Spermosens" or the "Company") today announces the outcome of the TO3 series of warrants, issued in connection with the rights issue announced on 20 February 2024.
Spermosens secures SEK 10.8 million strategic investment through directed issue, fulfilling capital need until cash positive
Spermosens AB (publ) (“Spermosens” or the “Company”) has secured an investment of SEK 10.8 million through a directed issue from a consortium of American and European strategic investors. The investment, which does not include issuance of any warrants, provides funding until H2 2026, when the Company expects to reach cash flow positivity, primarily through income…
Spermosens announces last day of trading for warrants of series TO3
Spermosens AB ("Spermosens" or "the Company") announces that the last day of trading for the warrants of series TO3 on Spotlight Stock Market is 27 February 2025.
Spermosens AB announces shareholding changes following latest directed issue
Spermosens AB (publ) announces changes in its shareholding structure following the latest directed issue. An update of the shareholder structure was made prior to the extraordinary general meeting held on 17 February 2025.
Kommuniké från extra bolagsstämma i Spermosens AB (publ) den 17 februari 2025
Spermosens AB (publ) höll den 17 februari 2025 extra bolagsstämma varvid i huvudsak följande beslut fattades. Beslut om ändring av bolagsordningen Den extra bolagsstämman beslutade, i enlighet med styrelsens förslag, att bemyndiga styrelsen att ändra bolagets bolagsordning genom att anta nya gränser för aktiekapitalet respektive antalet aktier i syfte att möjliggöra emission av aktier och…
Announcement from the Extraordinary General Meeting of Spermosens AB (publ) on 17 February 2025
Spermosens AB (publ) held an Extraordinary General Meeting on 17 February 2025, during which the following key resolutions were adopted. Resolution to Amend the Articles of Association The Extraordinary General Meeting resolved, in accordance with the Board's proposal, to authorize the Board to amend the company's Articles of Association by adopting new limits for share…
Spermosens adjusts publication date for Year-end report 2024
Spermosens AB (publ) announces that the company’s Year-end report for 2024, originally scheduled for publication on February 12, 2025, has been postponed to February 13, 2025. The adjustment has been made to align with the calendar availability of the company’s Board of Directors.
Aktieägarna i Spermosens AB (publ), org.nr 559179-0380 (”Bolaget”), kallas till extra bolagsstämma den 17 februari 2025 kl. 15.00 i Bolagets lokaler på Medicon Village Scheeletorget 1, 223 81 i Lund.
Spermosens year-end status update: Strong progress and promising outlook for 2025
Spermosens AB (“Spermosens” or the “Company”) provides a year-end update on its progress in 2024, a transformative year marked by key achievements, new leadership and the execution of a revised strategy that has positioned the Company for success going forward.
Spermosens announces the last day of trading in BTU and the first day of trading in warrants series TO 5 and TO 6
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE The rights…
Spermosens carries out directed issues of approx. MSEK 5.59, takes up credit facility of MSEK 1.00, and receives proposal of directed issues of approx. MSEK 0.39
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALAND, JAPAN, HONG KONG, SOUTHKOREA, SINGAPORE, SOUTH AFRICA, SWITZERLAND, RUSSIA OR BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. The Board…
Spermosens announces positive results from ongoing clinical study
Spermosens AB ("Spermosens" or the "Company") is pleased to announce the first interim results from its ongoing clinical study aimed at validating the diagnostic value of the patented JUNO-Checked system. The study is progressing as planned, and the first results are now being presented according to schedule. The first interim results from the clinical study…
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE On 3…
The subscription period in Spermosens’ rights issue of units ends on Monday, 25 November 2024
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE Monday, 25…
Spermosens' commercial strategy targets billion-dollar sperm bank market through global partnerships
Spermosens AB ("Spermosens" or the "Company") is pleased to provide an update on its progress in securing commercial partnerships and licensing agreements for its unique and patented JUNO-Checked system, designed to address critical unmet needs in male fertility diagnostics. As part of its commercial strategy, the Company is actively pursuing partnerships in key markets, including…
Spermosens provides update on clinical study progress
Spermosens AB ("Spermosens" or the "Company") is pleased to provide an update on its ongoing clinical study at Reproductive Medicine Center (RMC) in Malmö. This study, which evaluates the diagnostic relevance of the second-generation JUNO-Checked technology, is a significant step toward advancing personalized IVF treatments and supporting sperm banks in identifying the best possible donors.…
The subscription period in Spermosens’ rights issue of units begins today
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE Today, 11…
Spermosens publishes information memorandum due to upcoming rights issue of units
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE The Board…
Spermosens announces advancements in second-generation JUNO-Checked system
Spermosens AB ("Spermosens" or the "Company") is pleased to share additional information on the enhanced capabilities of its second-generation JUNO-Checked system, a significant advancement in male fertility diagnostics. JUNO-Checked is the first device that enables clinicians and researchers to measure sperm binding capacity - a critical parameter that complements current analyses in IVF clinics and…
Announcement from the Extraordinary General Meeting of Spermosens AB (publ)
Spermosens AB ("Spermosens" or the "Company") held an Extraordinary General Meeting today, 4 November 2024. At the meeting, the shareholders approved all previously announced proposals. The decisions can be summarized as follows: The meeting resolved to reduce the share capital without cancelling shares, to cover losses, through an amendment of the Articles of Association and…
Spermosens reduces spending by focusing on clinical study and business development
Spermosens AB ("Spermosens" or the "Company") is pleased to announce updates to its cost structure following the revised strategy. Over the past months, the Company has effectively adapted the organization to align with a new focus on the clinical study and business development, reducing overall spending and investment needs by more than 50%.
Spermosens reports strong progress in clinical study
Spermosens AB ("Spermosens" or the "Company") is pleased to announce strong progress in its ongoing clinical study at Reproductive Medicine Center (RMC) in Malmö, where the Company is evaluating its innovative JUNO-Checked technology. The study, designed to demonstrate the diagnostic relevance of JUNO-Checked in addressing male infertility, is progressing ahead of expectations with a strong…
Spermosens signs memorandum of understanding for commercial partnership in Japan
Spermosens AB ("Spermosens" or the "Company") is pleased to announce the signing of a Memorandum of Understanding (MoU) with a well established undisclosed Japanese company to explore a commercial partnership in Japan. This MoU lays the framework and intentions for discussions regarding the distribution and commercialization of Spermosens' fertility diagnostic product, JUNO-Checked, in Japan. Potential…
Spermosens receives notice of allowance for broad US patent covering JUNO-Checked technology
Spermosens AB (publ) (“Spermosens” or the “Company”) is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the Company's second patent in the US, covering its innovative JUNO-Checked technology. The newly allowed patent, "Biosensor for Male Infertility" (Application no. 17/260,609), encompasses a broader range of…
Spermosens recruits first couple for clinical study on next-generation male fertility diagnostic product
Spermosens AB (“Spermosens” or the “Company”) is pleased to announce a significant milestone in its clinical study of the next-generation fertility diagnostic product. The first couple has now been recruited for the study, which is designed to assess the diagnostic value of JUNO-Checked in male infertility. The clinical study, currently underway at the Reproductive Medicine…
Kallelse till extra bolagsstämma i Spermosens AB (publ) för beslut om emission
Aktieägarna i Spermosens AB (publ), org.nr 559179–0380, (”Spermosens” eller ”Bolaget”) kallas härmed till extra bolagsstämma den 4 november 2024 kl. 16:00 på The Spark, Medicon Village, Scheeletorget 1, Lund. På den extra bolagsstämman ska ägarna ta ställning till förslag om minskning av aktiekapitalet, emission med företrädesrätt för aktieägare för att ta in ytterligare kapital, samt…
Spermosens carries out a rights issue of units of approximately SEK 22.7 million
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE Today, the…
Spermosens next-generation male fertility diagnostic product ready for clinical study
Spermosens AB ("Spermosens" or the "Company") is pleased to announce the development of the next-generation of its JUNO-Checked device, a groundbreaking product designed to assess male fertility potential. Developed in collaboration with Flex Medical Solutions (FMS), this next-generation JUNO-Checked device will play a pivotal role in the upcoming clinical study, which has recently received ethical…
Spermosens passes an important milestone receiving approval for significant clinical study.
Spermosens AB announces that the Swedish Ethical Review Authority has given approval for the company’s application to start a clinical study at Reproductive Medicine Center (RMC) in Malmö with JUNO-Checked to evaluate sperm quality for couples undergoing fertility treatment. This means that the company now takes the next step in validating diagnostic use of JUNO-Checked.
Spermosens AB (publ) INTERIM REPORT JANUARY - JUNE 2024
The revised strategy positions Spermosens optimally to unlock the full potential of its groundbreaking product. Spermosens AB's interim report for the period January - June 2024, is now available on the Company's website and attached to this press release.
Spermosens announce a revised strategy emphasizing an ambitious clinical study, commercial partnerships, and operational efficiency. Starting in Q3 2024, the company will initiate a clinical study at the Reproductive Medicine Center (RMC) in Malmö to demonstrate the diagnostic value of its unique JUNO-Checked product. Spermosens will intensify business development globally to identify the right commercial…
Spermosens AB (publ) offentliggör delårsrapport januari - mars 2024
Spermosens AB delårsrapport för perioden januari - mars 2024, finns nu tillgänglig på Bolagets hemsida samt bifogad i detta pressmeddelande. Spermosens stärker fokuset på produktutveckling och värdeskapande.
Vid årsstämman i Spermosens AB (publ), org.nr. 559179–0380, den 10 maj 2024 fattades bland annat följande beslut. För mer information om innehållet i besluten hänvisas till kallelsen till årsstämman samt förslag till beslut, som tidigare har publicerats och finns tillgängliga på bolagets hemsida, www.spermosens.com
Spermosens AB (publ) offentliggör utfall i företrädesemission och meddelar flaggning
EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, SINGAPORE, NYA ZEELAND, JAPAN, SYDKOREA, KANADA, SCHWEIZ, HONGKONG, BELARUS, RYSSLAND ELLER SYDAFRIKA ELLER NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV DETTA PRESSMEDDELANDE SKULLE VARA OLAGLIG ELLER KRÄVA YTTERLIGARE REGISTRERINGS- ELLER ANDRA ÅTGÄRDER. YTTERLIGARE RESTRIKTIONER ÄR TILLÄMPLIGA. SE…
Spermosens AB meddelar att det singaporianska patentverket (Singapore Patent Office), har godkänt patent 11202100358V. Spermosens erhåller därmed skydd i Singapore för sin medicintekniska produkt inklusive biosensorn, och dess användning för selektion av spermier lämpliga för In Vitro Fertilisering (IVF-behandling). Patentet ger möjlighet till exklusivitet på den singaporianska marknaden till den 23 augusti 2039.
KORRIGERING: Spermosens årsredovisning för 2023 har idag publicerats på bolagets webbplats.
Årsredovisningen finns tillgänglig på: https://spermosens.com/investors/financial-reports/ Bolagets revisor har i sin revisionsberättelse på sidan 1 kommenterat väsentliga osäkerheter avseende antagandet om fortsatt drift. “Vi vill fästa uppmärksamheten på informationen i förvaltningsberättelsen om bolagets fortsatta finansiering och särskilt på uppgifterna under rubriken Likviditet, av vilka framgår att bolagsstämman under mars 2024 godkänt en av styrelsen beslutad nyemission…
Spermosens årsredovisning för 2023 har idag publicerats på bolagets webbplats.
Årsredovisningen finns tillgänglig på: https://spermosens.com/investors/financial-reports/ För mer information vänligen kontakta: Ulrik Nilsson, CEO info@spermosens.com +46 (0) 72 888 28 11 Spermosens AB (publ) Spermosens mål är att förbättra manlig fertilitetsdiagnostik och behandling genom introduktion av banbrytande produkter. Spermosens första patenterade produkt JUNO-Checked mäter bindningsförmågan mellan spermie och äggcell, vilket är en förutsättning för naturlig befruktning.…
KALLELSE TILL ÅRSSTÄMMA 2024 I SPERMOSENS AB (publ)
Välkommen till Spermosens AB:s, org. nr. 559179–0380, årsstämma fredagen den 10 maj 2024, kl. 13.00 på Scheeletorget 1, Medicon Village, The Spark, Lund. Inregistrering till stämman börjar kl. 12.30.
Spermosens AB (publ) offentliggör EU-tillväxtprospekt med anledning av företrädesemission av units
EJ FÖR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING, VARE SIG DIREKT ELLER INDIREKT, I ELLER TILL USA, AUSTRALIEN, SINGAPORE, NYA ZEELAND, JAPAN, SYDKOREA, KANADA, SCHWEIZ, HONGKONG, BELARUS, RYSSLAND ELLER SYDAFRIKA ELLER NÅGON ANNAN JURISDIKTION DÄR OFFENTLIGGÖRANDE, DISTRIBUTION ELLER PUBLICERING AV DETTA PRESSMEDDELANDE SKULLE VARA OLAGLIG ELLER KRÄVA YTTERLIGARE REGISTRERINGS- ELLER ANDRA ÅTGÄRDER. YTTERLIGARE RESTRIKTIONER ÄR TILLÄMPLIGA. SE…
Spermosens AB (publ) säkerställer 84 procent teckningsgrad i förestående företrädesemission
För att ytterligare säkerställa teckningsgraden av den förestående företrädesemissionen om cirka 28,8 MSEK har styrelsen för Spermosens AB (publ) (”Spermosens” eller ”Bolaget”) ingått avtal med VD Ulrik Nilsson om en så kallad top-down-garanti om cirka 1,2 MSEK. Ingen ersättning utgår för det lämnade garantiåtagandet.
We may request cookies to be set on your device. We use cookies to let us know how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refuseing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
Other external services
We use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
Privacy Policy
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
